相似文献
1
Development of potent μ and δ opioid agonists with high lipophilicity.
J Med Chem. 2011 Jan 13;54(1):382-6. doi: 10.1021/jm100982d. Epub 2010 Dec 3.
2
Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors.
J Med Chem. 2007 Nov 1;50(22):5528-32. doi: 10.1021/jm061465o. Epub 2007 Oct 10.
3
Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.
J Med Chem. 2007 Jun 14;50(12):2779-86. doi: 10.1021/jm061369n. Epub 2007 May 22.
4
Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
J Med Chem. 2006 May 18;49(10):2868-75. doi: 10.1021/jm050921q.
5
Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.
J Med Chem. 2005 Jan 27;48(2):586-92. doi: 10.1021/jm049384k.
6
Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice.
J Pharmacol Exp Ther. 2014 Mar;348(3):383-92. doi: 10.1124/jpet.113.208108. Epub 2013 Dec 17.
7
A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
J Med Chem. 2008 Mar 13;51(5):1369-76. doi: 10.1021/jm070332f. Epub 2008 Feb 12.
8
The cis-4-amino-L-proline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues.
J Med Chem. 2012 Apr 12;55(7):3027-35. doi: 10.1021/jm201402v. Epub 2012 Mar 22.
9
Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
J Med Chem. 2004 Jul 1;47(14):3591-9. doi: 10.1021/jm030649p.
10
Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
J Med Chem. 2007 Jan 25;50(2):328-33. doi: 10.1021/jm060721u.
引用本文的文献
1
Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery.
J Med Chem. 2024 Nov 28;67(22):19932-19965. doi: 10.1021/acs.jmedchem.4c00110. Epub 2024 Nov 11.
2
Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.
ACS Chem Neurosci. 2022 Dec 21;13(24):3608-3628. doi: 10.1021/acschemneuro.2c00526. Epub 2022 Nov 30.
3
Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.
Biomolecules. 2022 Sep 5;12(9):1241. doi: 10.3390/biom12091241.
4
The Dose-Dependent Effects of Multifunctional Enkephalin Analogs on the Protein Composition of Rat Spleen Lymphocytes, Cortex, and Hippocampus; Comparison with Changes Induced by Morphine.
Biomedicines. 2022 Aug 14;10(8):1969. doi: 10.3390/biomedicines10081969.
5
C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters.
Bioorg Med Chem. 2021 Dec 1;51:116509. doi: 10.1016/j.bmc.2021.116509. Epub 2021 Nov 11.
6
Multifunctional Enkephalin Analogs with a New Biological Profile: MOR/DOR Agonism and KOR Antagonism.
Biomedicines. 2021 May 31;9(6):625. doi: 10.3390/biomedicines9060625.
7
In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.
Int J Mol Sci. 2020 Oct 19;21(20):7738. doi: 10.3390/ijms21207738.
8
Efficient Synthesis of Norbuprenorphines Coupled with Enkephalins and Investigation of Their Permeability.
Iran J Pharm Res. 2019 Summer;18(3):1277-1287. doi: 10.22037/ijpr.2019.14712.12602.
9
In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Br J Pharmacol. 2018 Jun;175(11):2013-2027. doi: 10.1111/bph.14148. Epub 2018 Apr 24.
10
Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.
J Heterocycl Chem. 2017 Mar;54(2):1228-1235. doi: 10.1002/jhet.2696. Epub 2016 Jun 1.
本文引用的文献
1
Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors.
J Med Chem. 2007 Nov 1;50(22):5528-32. doi: 10.1021/jm061465o. Epub 2007 Oct 10.
2
Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors.
Bioorg Med Chem Lett. 2007 Apr 15;17(8):2161-5. doi: 10.1016/j.bmcl.2007.01.114. Epub 2007 Feb 8.
3
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
J Med Chem. 2006 Mar 9;49(5):1773-80. doi: 10.1021/jm050851n.
4
Dmt and opioid peptides: a potent alliance.
Biopolymers. 2003;71(2):86-102. doi: 10.1002/bip.10399.
5
Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors.
J Pharmacol Exp Ther. 2002 Jul;302(1):188-96. doi: 10.1124/jpet.302.1.188.
6
Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs.
J Pharmacol Exp Ther. 1993 Sep;266(3):1649-55.
7
Quantitative assessment of tactile allodynia in the rat paw.
J Neurosci Methods. 1994 Jul;53(1):55-63. doi: 10.1016/0165-0270(94)90144-9.
8
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.
Pain. 1988 Jan;32(1):77-88. doi: 10.1016/0304-3959(88)90026-7.
9
Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse.
J Pharmacol Exp Ther. 1990 Aug;254(2):683-9.
10
Distribution and analgesia of [3H][D-Pen2, D-Pen5]enkephalin and two halogenated analogs after intravenous administration.
J Pharmacol Exp Ther. 1991 Dec;259(3):1109-17.
Zotero 插件